StockData
Arrowhead Pharmaceuticals, Inc. logo

Arrowhead Pharmaceuticals, Inc. (ARWR) stock

ARWRNasdaqPharmaceutical PreparationsFiscal year ends September 30
Financials through Q3 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Nov 12, 2026Score 5/3035% above fair value
$42.99−1.22 (-2.76%)

Close on Nov 17, 2026Market cap $6.07BP/E –Yield –

Arrowhead Pharmaceuticals price to book ratio

The price-to-book ratio is market cap divided by shareholders' equity.

Arrowhead Pharmaceuticals's price to book ratio was 15.0× on Nov 11, 2026, against 15.3× a year earlier. Over the last 5 years it ranged from 3.2× to 45.2×, with a median of 12.1×.

Price to Book Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202615.0×−4.4
2025Dec 31, 202519.3×+6.7
2024Dec 31, 202412.6×+0.5
2023Dec 29, 202312.1×+1.3
2022Dec 30, 202210.8×−6.1
2021Dec 31, 202116.9×−0.1
2020Dec 31, 202017.0×−7.8
2019Dec 31, 201924.8×+13.3
2018Dec 31, 201811.5×+8.1
2017Dec 29, 20173.4×+2.2
2016Dec 30, 20161.1×−2.2
2015Dec 31, 20153.3×+0.9
2014Dec 31, 20142.4×−10.4
2013Dec 31, 201312.8×+9.9
2012Dec 31, 20122.9×+0.1
2011Dec 30, 20112.8×−4.3
2010Dec 31, 20107.1×–

More Arrowhead Pharmaceuticals figures

See a number that looks wrong?